help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 44, No. 6 1203-1205
doi:10.1210/jcem-44-6-1203
Copyright © 1977 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ZUMOFF, B.
Right arrow Articles by HELLMAN, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ZUMOFF, B.
Right arrow Articles by HELLMAN, L.

The Effect of 7β, 17{alpha}-Dimethyltestosterone (Calusterone®) on Testosterone Metabolism in Women with Advanced Breast Cancer

BARNETT ZUMOFF, JOSEPH LEVIN, H. LEON BRADLOW and LEON HELLMAN

Department of Oncology and the Institute for Steroid Research, Montefiore Hospital and Medical Center Bronx, New York

Calusterone® (7β, 17{alpha}-dimethyltestosterone) is a 17-alkylated, orally active androgenic steroid used in the treatment of breast cancer. The effect of this steroid on the metabolism of 14C-testosterone and the excretion of endogenous urinary androgen metabolites has been studied in four patients with breast cancer. Total glucuronide metabolites of the tracer decreased significantly, the androsterone/etiocholanolone ratio rose by a factor of 2–4, and there was increased formation of uncharacterized polar metabolites. There was no significant change in either the sum of the excretion of endogenous androgen metabolites or the androsterone/etiocholanolone ratio. The changes resemble those we have seen in cirrhosis of the liver. It is concluded that the effects of Calusterone on testosterone metabolism, like its effects on cortisol or estradiol metabolism, represent nonspecific effects of an orally administered 17-alkylated steroid on hepatic structure and function, and probably bear no relationship to its therapeutic effect in breast cancer.

Supported in part by grants CA-07304 from the National Cancer Institute and RR-53 from the General Clinical Research Centers Branch, National Institutes of Health, Bethesda, Md.

Received November 29, 1976.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1977 by The Endocrine Society